Literature DB >> 26269192

Propranolol Decreases Proliferation of Endothelial Cells Transformed by Kaposi's Sarcoma-Associated Herpesvirus and Induces Lytic Viral Gene Expression.

Shane C McAllister1, Ryan S Hanson2, Rory D Manion2.   

Abstract

Kaposi's sarcoma (KS) is common in Africa, but economic constraints hinder successful treatment in most patients. Propranolol, a generic β-adrenergic antagonist, decreased proliferation of KS-associated herpesvirus (KSHV)-infected cells. Downregulation of cyclin A2 and cyclin-dependent kinase 1 (CDK1) recapitulated this phenotype. Additionally, propranolol induced lytic gene expression in association with downregulation of CDK6. Thus, propranolol has diverse effects on KSHV-infected cells, and this generic drug has potential as a therapeutic agent for KS.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26269192      PMCID: PMC4621132          DOI: 10.1128/JVI.01569-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

Review 1.  Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.

Authors:  Shane C McAllister; Klaus Früh; Ashlee V Moses
Journal:  Pharmacogenomics       Date:  2005-04       Impact factor: 2.533

2.  Activation of cyclin A gene expression by the cyclin encoded by human herpesvirus-8.

Authors:  D Duro; A Schulze; B Vogt; J Bartek; S Mittnacht; P Jansen-D ºrr
Journal:  J Gen Virol       Date:  1999-03       Impact factor: 3.891

3.  Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus.

Authors:  Camilo Raggo; Rebecca Ruhl; Shane McAllister; Henry Koon; Bruce J Dezube; Klaus Früh; Ashlee V Moses
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

4.  Long-term infection and transformation of dermal microvascular endothelial cells by human herpesvirus 8.

Authors:  A V Moses; K N Fish; R Ruhl; P P Smith; J G Strussenberg; L Zhu; B Chandran; J A Nelson
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Discovery and evaluation of dual CDK1 and CDK2 inhibitors.

Authors:  Marc Payton; Grace Chung; Peter Yakowec; Andrew Wong; Dave Powers; Ling Xiong; Nancy Zhang; Juan Leal; Tammy L Bush; Vincent Santora; Ben Askew; Andrew Tasker; Robert Radinsky; Richard Kendall; Steve Coats
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

Review 6.  Treatment of Kaposi's sarcoma in HIV-1 infected individuals with emphasis on resource poor settings.

Authors:  M Dedicoat; M Vaithilingum; R Newton
Journal:  Cochrane Database Syst Rev       Date:  2003

7.  Kaposi sarcoma-associated herpesvirus (KSHV) induces heme oxygenase-1 expression and activity in KSHV-infected endothelial cells.

Authors:  Shane C McAllister; Scott G Hansen; Rebecca A Ruhl; Camilo M Raggo; Victor R DeFilippis; Deborah Greenspan; Klaus Früh; Ashlee V Moses
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

8.  Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.

Authors:  H P Gerber; A McMurtrey; J Kowalski; M Yan; B A Keyt; V Dixit; N Ferrara
Journal:  J Biol Chem       Date:  1998-11-13       Impact factor: 5.157

Review 9.  Cyclin A in cell cycle control and cancer.

Authors:  C H Yam; T K Fung; R Y C Poon
Journal:  Cell Mol Life Sci       Date:  2002-08       Impact factor: 9.261

10.  Human cytomegalovirus protects endothelial cells from apoptosis induced by growth factor withdrawal.

Authors:  Marcella Billstrom Schroeder; Robert Christensen; G Scott Worthen
Journal:  J Clin Virol       Date:  2002-08       Impact factor: 3.168

View more
  5 in total

1.  An In Vitro Model for Studying Cellular Transformation by Kaposi Sarcoma Herpesvirus.

Authors:  Shane C McAllister; Ryan L Hanson; Kyleen N Grissom; Sara Botto; Ashlee V Moses
Journal:  J Vis Exp       Date:  2017-08-25       Impact factor: 1.355

Review 2.  Kaposi sarcoma.

Authors:  Ethel Cesarman; Blossom Damania; Susan E Krown; Jeffrey Martin; Mark Bower; Denise Whitby
Journal:  Nat Rev Dis Primers       Date:  2019-01-31       Impact factor: 52.329

3.  Use of non-selective β-blockers is associated with decreased tumor proliferative indices in early stage breast cancer.

Authors:  Alexa Montoya; Clarissa N Amaya; Andres Belmont; Nabih Diab; Richard Trevino; Geri Villanueva; Steven Rains; Luis A Sanchez; Nabeel Badri; Salman Otoukesh; Ali Khammanivong; Danielle Liss; Sarah T Baca; Renato J Aguilera; Erin B Dickerson; Alireza Torabi; Alok K Dwivedi; Aamer Abbas; Karinn Chambers; Brad A Bryan; Zeina Nahleh
Journal:  Oncotarget       Date:  2017-01-24

4.  Regression of primary cardiac angiosarcoma and metastatic nodules following propranolol as a single agent treatment.

Authors:  Dana C Galván; Anoop P Ayyappan; Brad A Bryan
Journal:  Oncoscience       Date:  2018-10-11

5.  Oncogenic Herpesvirus Engages Endothelial Transcription Factors SOX18 and PROX1 to Increase Viral Genome Copies and Virus Production.

Authors:  Krista Tuohinto; Veijo Nurminen; Silvia Gramolelli; Endrit Elbasani; Thomas Günther; Riikka E Kallinen; Seppo P Kaijalainen; Raquel Diaz; Adam Grundhoff; Caj Haglund; Joseph M Ziegelbauer; Teijo Pellinen; Mark Bower; Mathias Francois; Päivi M Ojala
Journal:  Cancer Res       Date:  2020-06-09       Impact factor: 12.701

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.